Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.30 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.30 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24149577 | 0.95 | DOT1L (0.33) | CYP3A4CYP2C9DOT1LTMPRSS2 | |
| SCHEMBL24148975 | 0.95 | BTN3A1 (0.35) | CYP3A4CYP2C9DOT1LPOLRMTBTN3A1 | |
| SCHEMBL24148931 | 0.95 | DOT1L (0.33) | CYP3A4CYP2C9DOT1L | |
| SCHEMBL25013555 | 0.94 | DOT1L (0.32) | CYP3A4CYP2C9DOT1LPOLRMT | |
| SCHEMBL24148764 | 0.94 | DOT1L (0.32) | CYP3A4CYP2C9DOT1L | |
| SCHEMBL24149679 | 0.94 | DOT1L (0.33) | CYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL25013392 | 0.94 | DOT1L (0.32) | CYP3A4CYP2C9DOT1L | |
| SCHEMBL24148691 | 0.94 | DOT1L (0.34) | CYP3A4CYP2C9DOT1L | |
| SCHEMBL25012770 | 0.94 | DOT1L (0.33) | CYP3A4CYP2C9DOT1L | |
| SCHEMBL24148568 | 0.93 | DOT1L (0.32) | CYP3A4CYP2C9DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040586-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021262826-A2 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040586-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | CYP3A4 1932/4885CYP2C9 2637/4885DOT1L 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.